Dr Reddy's shares remain under pressure after its semaglutide production halt. Here's what leading brokerages expect for earnings, target prices and recovery.

Routine' network updates aren't low-risk; modern systems are so interconnected that a tiny tweak can break hidden ...

Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide ...

The brokerage's optimism comes despite Dr Reddy's announcing that certain batches of semaglutide injectables failed quality ...

Enterprise AI budgets are surging, but the money is not flowing where most people expect. The companies winning on social ...

More than 2.5 million bottles of a prescription steroid eye drop used to treat inflammation have been flagged by the FDA over ...

When agents move from merely reading data to acting on it, the enterprise attack surface expands exponentially. Without a ...

The company that builds the world's most advanced chips is about to tell investors how hot AI demand really is.

Wall Street's biggest banks are split on two AI chip stocks. Here's why they're backing Marvell Technology while remaining ...

By simulating machining operations before production begins, manufacturers can reduce dependence on individual experience or ...

From legacy assessment to AI-ready cloud architecture, Excellent Webworld's global recognition by Clutch reflects 15 ...